----item----
version: 1
id: {F64316B6-B4AE-46F5-AFCC-7B0A9B5CF836}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/04/03/Shield to develop screening kits for cardiac risk
parent: {2F783E2E-0178-43AE-8466-15C21F54A536}
name: Shield to develop screening kits for cardiac risk
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 4cc121fd-a426-4120-bac7-cfbc3cb94acd

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 720

<p>Shield Diagnostics (UK) is to collaborate with Scottish Enterprise Tayside (SET) to develop a panel of cardiovascular tests to screen for risk of heart attack. Under the deal, SET will provide a percentage of the funding in return for a royalty on product sales. Shield will extend its programme on activated factor XII (AFT) to develop additional tests for activated factor VII, fibrinogen, d-dimer and von Willebrand factor, amongst others. These will be incorporated into a combined kit that will give a complete picture of the state of activation of the clotting system. Shield expects to launch the kit within 12 to 18 months and generate sales of &pound;1 million ($1.6 million) annually within three years.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 50

Shield to develop screening kits for cardiac risk:
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 720

<p>Shield Diagnostics (UK) is to collaborate with Scottish Enterprise Tayside (SET) to develop a panel of cardiovascular tests to screen for risk of heart attack. Under the deal, SET will provide a percentage of the funding in return for a royalty on product sales. Shield will extend its programme on activated factor XII (AFT) to develop additional tests for activated factor VII, fibrinogen, d-dimer and von Willebrand factor, amongst others. These will be incorporated into a combined kit that will give a complete picture of the state of activation of the clotting system. Shield expects to launch the kit within 12 to 18 months and generate sales of &pound;1 million ($1.6 million) annually within three years.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 49

Shield to develop screening kits for cardiac risk
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950403T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950403T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950403T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052043
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 50

Shield to develop screening kits for cardiac risk:
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

253812
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184038Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

4cc121fd-a426-4120-bac7-cfbc3cb94acd
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184038Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
